Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients

International Angiology

Volumn 32, Issue 1, 2013, Pages 85-93

  Farah, R ^a   Khamisy Farah, R ^b   Shurtz Swirski, R ^a  

^a Rebecca Sieff Government Hospital   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Hypertension; Inflammation; Neutrophils; Oxidative stress

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; INSULIN; LERCANIDIPINE; TRANSFERRIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; APOPTOSIS; ARTICLE; BORDERLINE HYPERTENSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEUKOCYTE; MALE; MEAN ARTERIAL PRESSURE; POLYMORPHONUCLEAR CELL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; AGED; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84877319068     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
2. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, Levy D. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-7. (Pubitemid 29181641)
3. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989;2:419-23. (Pubitemid 19168223)
4. The 1993 Guidelines for the management of mild hypertension: memorandum from a who/ish meeting. Blood pressure 1993;2:86-100.
5. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995;25:155-61.
6. Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB Jr, Henson PM, Worthen GS. Neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;77:1233-43.
7. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76. (Pubitemid 19106873)
8. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998;11:921-8. (Pubitemid 28378404)
9. Sela S, Shurtz-Swirski R, Farah R, Levy R, Shapiro G, Chezar J, Shasha SM, Kristal B. A link between polymorphonuclear leukocyte intracellular calcium, plasma insulin, and essential hypertension. Am J Hypertens 2002;15:291-5. (Pubitemid 34408966)
10. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B. The primed peripheral polymorphonuclear leukocyte - a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005;16:2431-2438 (Pubitemid 41725061)
11. Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, Kristal B. Involvement of polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetes. Diabetes Care 24:104-110, 2001 (Pubitemid 32104229)
12. Sela S, Shurtz-Swirski R, Awad J, Shapiro G, Nasser L, Shasha SM, Kristal B. The involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in cigarette smokers. IMAJ 4:1015-1019, 2002
13. Tulenko TN, Sumner AE, Chen M, Huang Y, Laury-Kleintop L, Ferdinand FD. The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am Heart J 2001;141:S1-11
14. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102:1503-1510
15. Hernandez RH, Armas-Hernandez MJ, Velasco M, Israili ZH, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003;10:409-414
16. Napoli C, Salomone S, Godfraind T, Palinski W, Capuzzi DM, Palumbo G, D'Armiento FP, Donzelli R, de Nigris F, Capizzi RL, Mancini M, Gonnella JS, Bianchi A. 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke 1999;30:1907-1915. (Pubitemid 29411835)
17. Toyo-oka T, Nayler WG. Third generation calcium entry blockers. Blood pressure 1996;5:206-208 (Pubitemid 26231639)
18. Bang LM, Chapman TM, Goa KL. Lercanidipine. A review of its efficacy in the management of hypertension. Drugs 2003;63:2449-2472 (Pubitemid 37392913)
19. Klebanoff SJ, Clark RA. Iodination by human polymorphonuclear leukocytes: a re-evaluation. J Lab Clin Med 1977;89:675-686 (Pubitemid 8082921)
20. Babior BM, Kipnes RS, Curnutte JJ. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52:741-744
21. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD, Lubin BH. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled Annexin V. Blood 1996;87:1179-1187 (Pubitemid 26043547)
22. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF Jr, Lowrie EG. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003;18:1167-1173 (Pubitemid 36722520)
23. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, Young EW. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62:2238-2245 (Pubitemid 35366181)
24. Erlinger TP, Tarver-Carr ME, Powe NR, Appel LJ, Coresh J, Eberhardt MS, Brancati FL. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis 2003;42:256-263 (Pubitemid 36944432)
25. Tsirpanlis G, Bagos P, Ioannou D, Bleta A, Marinou I, Lagouranis A, Chatzipanagiotou S, Nicolaou C. Serum albumin: a late-reacting negative acute-phase protein in clinically evident inflammation in dialysis patients. Nephrol Dial Transplant 2005;20:658-659
26. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965 (Pubitemid 32568149)
27. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242 (Pubitemid 29056365)
28. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-547 (Pubitemid 26304398)
29. De Fronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194
30. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulenemia, and coronary heart disease. Diabetology 1994;37:948-952 (Pubitemid 24288037)
31. Ohno Y, Matsuo K, Suzuki H, Tanase H, Ikeshima H, Takano T, Saruta T. Genotypes of sarco (endo) plasmic reticulum Ca++ -dependent ATPase II gene in substrains of spontaneously hypertensive rats. J Hypertens 1996;14:271-287
32. Ware JA, Clark AB, Smith M, Salzman EW. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 1989;73:172-176 (Pubitemid 19040972)
33. Draznin B. Cytosolic calcium and insulin resistance. Am J Kidney Dis 1993;21:32-38 (Pubitemid 23180375)
34. Claus TH, Lowe DB, Liang Y, Salhanick AI, Lubeski CK, Yang L, Lemoine L, Zhu. J, Clairmont KB. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J Pharmacol Exp Then 2005 Dec;315(3):1396-402 (Pubitemid 41635430)
35. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J. Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res 2005;28:107-112 (Pubitemid 40663060)
36. Tomlinson B, Benzie IF. Antioxidant effect of lercanidipine. Hypertension 2003;42:10-11
37. Bellosta S, Bernini F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atheroscler Rep 2000;2:76-81
38. Farah R, Shurtz-Swirski R. The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients. Minerva Cardioangiol. 2008 Oct; 56(5):467-76.
39. Martinez ML, Rizzi E, Castro MM, Fernandes K, Bendhack LM, Gerlach RF, Tanus-Santos JE. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol. 2008 Dec 3;599(1-3):110-6
40. Wu JR, Liou SF, Lin SW, Chai CY, Dai ZK, Liang JC, Chen IJ, Yeh JL. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res. 2009 Jan;59(1):48-56. Epub 2008 Oct 5.